Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - drogy obštrukčnej choroby dýchacích ciest, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

boehringer ingelheim international gmbh, nemecko - tiotropiumbromid - 14 - bronchodilatantia, antiasthmatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

boehringer ingelheim international gmbh, nemecko - olodaterol a tiotrópiumbromid - 14 - bronchodilatantia, antiasthmatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

boehringer ingelheim international gmbh, nemecko - olodaterol - 14 - bronchodilatantia, antiasthmatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - teriflunomid - 59 - immunopraeparata

Európska únia - slovenčina - EMA (European Medicines Agency)

gmp-orphan sa - trientine tetrahydrochloride - hepatolentikulárna degenerácia - iné alimentárny trakt a metabolizmus výrobky, - cuprior je indikovaný na liečbu wilsonova choroba u dospelých, dospievajúcich a detí ≥ 5 rokov trpiace neznášanlivosťou d-penicilamín terapia.

Európska únia - slovenčina - EMA (European Medicines Agency)

gedeon richter - kariprazín hydrochlorid - schizofrénie - psycholeptika - reagila je indikovaná na liečbu schizofrénie u dospelých pacientov.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

chiesi pharmaceuticals gmbh, rakúsko - formoterol a beklometazón - 14 - bronchodilatantia, antiasthmatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

chiesi pharmaceuticals gmbh, rakúsko - formoterol a beklometazón - 14 - bronchodilatantia, antiasthmatica

Európska únia - slovenčina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - imunosupresíva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.